GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anupam Rasayan India Ltd

Anupam Rasayan India: Q1 FY27 Consolidated Revenue Rs 6,675 Mn, up 36% YoY

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 14 Aug 2026, 11:59 AM IST  ·  BSE ID: f89eecf7-44f8-4ff2-80d5-df7f40e8337b
View Original BSE Filing (PDF)
💡
In Simple Terms
Anupam Rasayan India saw higher sales and profit in Q1 FY27, secured a new potential deal, and achieved a production milestone.
🤖 AI Summary
  • Anupam Rasayan India Ltd reported Q1 FY27 consolidated Total Revenue of Rs 6,675 Mn, up 36% YoY.
  • EBITDA increased 35% YoY to Rs 1,749 Mn, maintaining a 26.2% EBITDA margin.
  • Profit After Tax (PAT) for Q1 FY27 was Rs 512 Mn, reflecting a 6% YoY growth.
  • Company became first globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
  • Signed a Letter of Intent with BASQUEVOLT, S.A. for potential US$300 million supply over ten years.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Total Revenue (Q1FY27)
Rs 6,675 Mn
36%
Total Revenue (Q1FY26)
Rs 4,907 Mn
EBITDA (Q1FY27)
Rs 1,749 Mn
35%
EBITDA (Q1FY26)
Rs 1,292 Mn
EBITDA Margin (Q1FY27)
26.2%
PAT (Q1FY27)
Rs 512 Mn
6%
PAT (Q1FY26)
Rs 485 Mn
🏢 How This Affects the Company
📈
Business Impact
The 36% YoY revenue growth suggests sustained demand across its specialty chemical businesses. The Letter of Intent with BASQUEVOLT, S.A. for a potential US$300 million over ten years indicates future revenue opportunities. Commercialization of ETFA using flow chemistry strengthens its position in complex fluorination.
💰
Financial Impact
Consolidated Total Revenue increased to Rs 6,675 Mn in Q1 FY27. EBITDA rose to Rs 1,749 Mn, with the EBITDA margin remaining at 26.2% compared to Q1 FY26. Profit After Tax grew to Rs 512 Mn.
⚙️
Operational Impact
The commercialization of Ethyl Trifluoroacetate via flow chemistry signifies an advancement in manufacturing processes and capabilities for complex fluorination. The progress on the proposed acquisition of Bliss GVS Pharma suggests an expansion of its pharmaceutical platform.
⚠️
Risk Impact
No new risks are introduced by this filing. The Letter of Intent represents a potential revenue opportunity, but its realization is subject to a definitive agreement.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
Shareholders are affected by the company's financial performance, with Q1 FY27 consolidated Total Revenue at Rs 6,675 Mn and PAT at Rs 512 Mn. The potential US$300 million deal could impact future earnings.
🔍
Management Signal
Management is signaling a focus on growth through business expansion, technological innovation like ETFA commercialization, and strategic acquisitions exemplified by the Bliss GVS Pharma acquisition progress.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Progress of proposed Bliss GVS Pharma acquisition.
Finalization of definitive agreement with BASQUEVOLT, S.A.
Q2 FY27 financial results for continued revenue and profit trends.
LOW RISK The filing indicates positive operational results and strategic initiatives, with no immediate new risks identified.
💡 Investor Takeaway
Anupam Rasayan India Ltd reported Q1 FY27 consolidated Total Revenue of Rs 6,675 Mn, up 36% YoY, and EBITDA of Rs 1,749 Mn, up 35% YoY. PAT increased 6% to Rs 512 Mn. A Letter of Intent for a potential US$300 million supply over ten years was also signed.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Total Revenue grew 36% YoY to Rs 6,675 Mn in Q1 FY27, reflecting sustained business momentum.
  • EBITDA increased 35% YoY to Rs 1,749 Mn while maintaining a robust 26.2% margin in Q1 FY27.

⚠️ Concerns

  • Profit After Tax growth of 6% YoY to Rs 512 Mn in Q1 FY27 was significantly lower than revenue and EBITDA growth.
  • The US$300 million revenue opportunity from BASQUEVOLT, S.A. is based on a Letter of Intent and is spread over ten years.
❓ Frequently Asked Questions
What was Anupam Rasayan India Ltd's consolidated Total Revenue for Q1 FY27?
Anupam Rasayan India Ltd reported a consolidated Total Revenue of Rs 6,675 Mn for the quarter ended June 30, 2026, which is up 36% YoY from Rs 4,907 Mn in Q1 FY26.
What was Anupam Rasayan India Ltd's EBITDA and EBITDA margin in Q1 FY27?
The consolidated EBITDA for Anupam Rasayan India Ltd in Q1 FY27 was Rs 1,749 Mn, a 35% YoY increase. The EBITDA margin stood at 26.2% for the quarter.
What was Anupam Rasayan India Ltd's Profit After Tax (PAT) for Q1 FY27?
Anupam Rasayan India Ltd's consolidated Profit After Tax (PAT) for Q1 FY27 was Rs 512 Mn, which represents a 6% YoY increase compared to Rs 485 Mn in Q1 FY26.
What significant technological milestone did Anupam Rasayan achieve in Q1 FY27?
Anupam Rasayan India Ltd became the first company globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry during Q1 FY27.
What is the potential value of the Letter of Intent signed by Anupam Rasayan India Ltd with BASQUEVOLT, S.A.?
Anupam Rasayan India Ltd signed a Letter of Intent with BASQUEVOLT, S.A. for a potential long-term supply representing a revenue opportunity of approximately US$300 million spread over ten years.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.